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Abstract
Background: The HIV-1 Rev protein is a key component in the early to late switch in HIV-1 splicing from
early intronless (e.g. tat, rev) to late intron-containing Rev-dependent (e.g. gag, vif, env) transcripts. Previous
results suggested that cis-acting sequences and inefficient 5' and 3' splice sites are a prerequisite for Rev
function. However, we and other groups have shown that two of the HIV-1 5' splice sites, D1 and D4, are
efficiently used in vitro and in vivo. Here, we focus on the efficiency of the HIV-1 3' splice sites taking into
consideration to what extent their intrinsic efficiencies are modulated by their downstream cis-acting
exonic sequences. Furthermore, we delineate their role in RNA stabilization and Rev function.
Results: In the presence of an efficient upstream 5' splice site the integrity of the 3' splice site is not
essential for Rev function whereas an efficient 3' splice site impairs Rev function. The detrimental effect of
a strong 3' splice site on the amount of Rev-dependent intron-containing HIV-1 glycoprotein coding (env)
mRNA is not compensatable by weakening the strength of the upstream 5' splice site. Swapping the HIV-
1 3' splice sites in an RRE-containing minigene, we found a 3' splice site usage which was variably dependent
on the presence of the usual downstream exonic sequence. The most evident activation of 3' splice site
usage by its usual downstream exonic sequence was observed for 3' splice site A1 which was turned from
an intrinsic very weak 3' splice site into the most active 3' splice site, even abolishing Rev activity.
Performing pull-down experiments with nuclear extracts of HeLa cells we identified a novel ASF/SF2-
dependent exonic splicing enhancer (ESE) within HIV-1 exon 2 consisting of a heptameric sequence motif
occurring twice (M1 and M2) within this short non-coding leader exon. Single point mutation of M1 within
an infectious molecular clone is detrimental for HIV-1 exon 2 recognition without affecting Rev-dependent
vif expression.
Conclusion: Under the conditions of our assay, the rate limiting step of retroviral splicing, competing
with Rev function, seems to be exclusively determined by the functional strength of the 3' splice site. The
bipartite ASF/SF2-dependent ESE within HIV-1 exon 2 supports cross-talk between splice site pairs across
exon 2 (exon definition) which is incompatible with processing of the intron-containing vif mRNA. We
propose that Rev mediates a switch from exon to intron definition necessary for the expression of all
intron-containing mRNAs.
Published: 04 December 2006
Retrovirology 2006, 3:89 doi:10.1186/1742-4690-3-89
Received: 18 September 2006
Accepted: 04 December 2006
This article is available from: http://www.retrovirology.com/content/3/1/89
© 2006 Kammler et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Retrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
Page 2 of 20
(page number not for citation purposes)
Background
During replication of the human immunodeficiency virus
type 1 (HIV-1) the viral (+)RNA genome is reverse tran-
scribed and integrated into the host cell genome. Tran-
scription of this provirus by the cellular RNA polymerase
II generates a polycistronic pre-mRNA that contains at
least four 5' splice sites (5'ss) D1-4 and eight 3' splice sites
(3'ss) A1, 2, 3, 4c, 4a, 4b, 5 and 7 that enable alternative
splicing of more than 40 different mRNAs. Additionally,
isolate specific (D5 and A6) and subgenomic construct-
specific usage of cryptic splice sites has also been reported
[1-4] (for a recent review see [5] and Fig. 1). Beside these
well-known 5'ss, additional sites might be present prefer-
entially serving as U1 snRNA binding sites to stabilize the
viral RNA rather than serving for transcript diversity (e.g.,
5'ss of exon 1a, [6]).
Replication of HIV-1 requires an early to late switch in
splicing from early intronless to late intron-containing
Rev-dependent mRNAs. The intronless transcripts of the
1.8-kb or "multiply spliced" class code for the regulatory
and accessory proteins Tat, Rev and Nef. Processing of
these transcripts is fully compatible with the model of
exon recognition. In the late phase, all transcripts of the
4.0-kb class coding for the Env, Vpu, Tat, Vpr and Vif pro-
teins contain at least one intronic sequence. However, due
to the variable inclusion of the small non-coding leader
exons 2 and/or 3 in some cases these so-called "partially
or incompletely spliced" mRNAs are even more often
spliced than the early "multiply spliced" Rev-independent
mRNAs (cf., the "partially or incompletely spliced"
1.2.3.5I env RNA vs. the "multiply spliced" Rev-independ-
ent 1.7 nef mRNA). Thus, the number of intron removals
is not decisive for Rev-dependence but rather the imple-
mentation of intron definition.
Whereas the early 1.8-kb mRNA species readily exit the
nucleus and undergo translation, the 4.0-kb and non-
spliced 9.0-kb mRNAs require Rev which overcomes the
restriction of nuclear export of intron-containing tran-
scripts by accessing the CRM1 nuclear export pathway
[7,8]. In particular, the viral transcripts encoding the Env,
Vpu, Vpr, Vif and structural viral Gag, Gag-Pro, and Gag-
Pro-Pol proteins include the tat/rev intron flanked by D4
and A7, which contains a complex secondary structure,
i.e., the Rev response element (RRE) which functions as
high-affinity binding site for Rev.
Even though the interactions between splicing and Rev-
dependent mRNA export are still not totally understood it
is commonly accepted that cis-acting sequences in gag/pol
and env [9-11], as well as inefficient splice sites [12,13],
are prerequisites for the Rev-regulated HIV-1 gene expres-
sion. In fact, based on their sequence-mediated intrinsic
strength, the HIV-1 splice acceptors are predicted to be
inefficient. They all contain suboptimal polypyrimidine
tracts (PPTs) interrupted by purines and, in some cases, by
other AG dinucleotides and branch point sequences
(BPSs) with 1–4 mismatches to U2 snRNA. For A2, A4a,
A5 and A7 even branching on uracil or guanine instead of
the typically used adenine has been reported [14,15].
Determination of the strength of a splice site however, is
exacerbated by the fact that its intrinsic strength can be
greatly modified, both positively as well as negatively, by
cis-acting splicing regulatory sequences called splicing
enhancers and silencers. Several cis-acting elements i.e.
splicing silencer elements, have been identified in the
HIV-1 genome. These serve as protein binding sites for
members of the heterogenous nuclear ribonucleoprotein
(hnRNP) family by down regulating splicing at the 3'
splice sites A2 [16], A3 [17,18], the HXB2-specific A6
[19,20] and A7 [17,21,22]. Interestingly, and also a priori
unexpectedly for inefficient splice sites, previous studies
have also mapped splicing enhancer sequences as binding
sites for SR proteins in exon 5 [23], the HXB2 specific exon
6 [20] and downstream of A7 [17,21,22,24-26]. Binding
of SR proteins downstream of a splice acceptor can
increase the efficiency of U2AF binding to the polypyrimi-
dine tract either by displacement of hnRNP A1 protein
that blocks access of spliceosomal components to the 3'ss
or by direct interaction between the RS domains of the SR
protein and U2AF35.
Previous experimental studies examining the strength of
HIV-1 3' splice sites support the predicted inefficiency of
these sites but did not take into account the influence of
all the cis-acting sequences which had not been identified
at that time [27]. Therefore, we were interested in examin-
ing the impact of the intronic sequence versus the cis-act-
ing, mostly exon-located, enhancer and silencer elements
on the strength of the retroviral 3'ss.
In a splice site swapping strategy we compared the splicing
efficiency of the HIV-1 3'ss A1, 2, 3, 4cab, 5 and 7 in the
presence and absence of their natural downstream exonic
sequences. Since HIV-1 exon 2 drastically increased usage
of the intrinsic weak splice site A1, which is required for
the  vif  mRNA, we characterized this newly identified
bipartite ESE and show that inactivation of the heptameric
sequence M1 within an infectious molecular clone specif-
ically impedes exon definition.
Results
A functional 3' ss is not necessary for Rev function
Binding of U1 snRNA to 5'ss D4 within a subgenomic env
mRNA has turned out to substantially increase the env
mRNA steady-state level. Therefore, the presence of D4
not only has been a prerequisite for splicing but also for
the nuclear export of unspliced RNA through the action ofRetrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
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Rev. To analyze whether 3'ss A7 also contributes to the
steady-state level of the glycoprotein mRNA we inacti-
vated 3'ss A7 and the two upstream minor 3'ss, A7a and
A7b [2-4], by silent point mutations (A7 -, Fig. 2A) ena-
bling analysis of these mutations in the glycoprotein-
mediated syncytia assay.
To verify that the introduced mutations did not lead to
activation of a cryptic 3'ss we additionally compared the
subgenomic HIV-1 transcripts by Northern blot analysis
of the respective poly(A)+ RNA fractions following tran-
sient transfection of HeLa-T4+ cells with either the subge-
nomic env expression vector SV E/X tat- rev- or SV E/X tat-
rev- A7- (Fig. 2B). Due to mutations of the tat and rev ATG
translational initiation codons, these vectors express nei-
ther Tat nor Rev. Thus, in the absence of Rev transfection
with SV E/X tat- rev- led almost exclusively to detection of
spliced mRNA (Fig. 2B, lane 1). In contrast, after cotrans-
fection with a Rev-expressing plasmid the majority of the
detected mRNA was the unspliced poly(A)+ glycoprotein
mRNA (Fig. 2B, lane 1'). As expected, mutations of all
three 3'ss, A7, A7a and A7b, led to complete loss of any
Alternative splicing of HIV-1 Figure 1
Alternative splicing of HIV-1. (A) Organization of the HIV-1 genome. Filled boxes indicate open reading frames present in 
all isolates, light grey boxes indicate the Tev orf which is isolate specific. The long terminal repeats (LTR) are present at both 
ends of the proviral DNA. (B) Localization of splice sites, splicing regulatory elements and the Rev responsive element (RRE). 
5' splice sites: D1a-5; 3' splice sites: A1-7. Splice sites A6/D5 are isolate specific and not functional in the isolate NL4/3 used in 
this study. Splice sites A1a/D1a defining exon 1a have been recently described [6]. The nomenclature of the 3'ss is according to 
Stoltzfus [17,18] and Purcell and Martin [2] (in brackets). Splicing regulatory elements: M1, M2 (this report); ESSV [16,64]; 
ESS2p [18]; ESE2/ESS2 [17,32,43,44,49]; GAR [23,28]; ESS/ESE [19,20]; ISS [22]; ESE3 [17,21,24,25,33,65]; ESS3a, b 
[17,21,24,33,66]. (C) Splicing pattern and proteins encoded by the different mRNA classes. The 1.8 and 4 kb mRNAs contain 
obligatory sequences (dark grey) as well as alternative sequences (light grey) due to alternative usage of the splice sites. The 
nuclear export of the 4 kb mRNAs and the genomic full-length 9 kb mRNA is dependent on Rev binding.
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detectable spliced transcript indicating that no cryptic
splice acceptor was significantly activated (lane 3). How-
ever, in the presence of Rev the amount of unspliced poly
(A)+ env mRNA was unaffected by the presence or absence
of a functional splice acceptor (cf. lane 1' with 3') demon-
strating that the 3'ss mutations did not decrease the pool
of unspliced poly (A)+ transcripts. This contrasted the pre-
viously shown 5'ss dependency of spliced and unspliced
transcripts [28] (cf. lane 1 with 4 and 1' with 4'), i.e. the
lack of U1 snRNA-binding to the 5'ss leads to env RNA
degradation (see hGH detectability in lanes 2, 4, 2', and
4'). The results of the Northern analysis were confirmed
by glycoprotein expression analyzed by Western blot and
syncytium formation (data not shown). Together these
results demonstrate that a 3'ss is dispensable for Rev-
mediated  env  expression. Moreover, these results show
3'ss A7 is nonessential for RNA stability and Rev responsiveness Figure 2
3'ss A7 is nonessential for RNA stability and Rev responsiveness. (A) Schematic drawing of the HIV-1 genome and of 
the subgenomic env expression plasmid SV E/X tat- rev-. LTR: long terminal repeat, SV40: SV40early promoter, pA: SV40 poly-
adenylation sequence. Nucleotide sequences of the 5'ss D4 and its mutations D4- and -1G3U as well as the 3'ss A7 and its 
mutations A7- and A7+ are shown beneath. The splice sites (grey squares, including the minor 3'ss 7a and 7b), the reported or 
supposed branch point sequence (bold, asterix indicates the branch point nucleotide) and the mutated nucleotides (underlined) 
are marked. In the 3'ss mutants the reading frame was kept unchanged except for position 703 (Val→Ala) in A7+. (B) HeLa-
T4+ cells were transiently transfected with the subgenomic env expression plasmids (SV E/X tat - rev -) containing either the 
wild type 5'ss D4 or the non functional D4- mutation combined with either the wild type 3'ss A7 or the A7- mutation in pres-
ence or absence of a Rev expression plasmid (SVcrev) as indicated above the lanes. The poly(A)+ RNA was analyzed by North-
ern blotting. s: spliced, us: unspliced transcript. Transfection efficiency was monitored by co-transfection of a human growth 
hormone (hGH) expressing plasmid (pXGH5).
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that the protective function of U1 snRNA binding is inde-
pendent of the recognition of the 3'ss during progression
of spliceosome formation.
To exclude the possibility that the requirement for U1
snRNA complementarity for protection of the transcript
was caused by an RNA surveillance mechanism detecting
a functional 3'ss in the absence of a 5'ss we mutated both
the 5'ss (D4-, Fig. 2A) and 3'ss (A7-) and analyzed the
steady-state levels of total poly(A)+ RNA. In the absence of
both the 5' and 3'ss RNA could still not be detected irre-
spective of the presence or absence of Rev (Fig. 2B, lanes 2
and 2'). This indicates that the U1 snRNA dependency for
the expression of this subgenomic env mRNA was not due
to an unpaired/cryptic splice site but was intrinsic to the
transcript sequence.
3'ss efficiency competes with Rev function
Increasing the complementarity between the 5'ss D4 and
U1 snRNA did not lead to a decrease in env expression,
indicating that even in the presence of a strong 5'ss Rev-
regulated env mRNA transport was not impaired [23,29].
To specifically investigate the influence of the strength of
the 3'ss on Rev-mediated glycoprotein expression we
improved the strength of 3'ss A7 in its context of a subge-
nomic glycoprotein expression vector. To achieve this, the
suboptimal BPS was attenuated and a new BPS with
higher complementarity to U2 snRNA was created further
downstream. Additionally, the canonical AG dinucle-
otides of the cryptic sites A7a and A7b were mutated to
prevent an interference with potentially binding splicing
factors and the pyrimidine content of the PPT (in the
region between the new BPS and the intron/exon border)
was increased from 48 % to 77 %. All these nucleotide
changes were introduced as silent mutations except for
one (Val to Ala at position 703), which was not expected
to influence the fusogenic activity of the glycoprotein (Fig.
2A, A7+).
As expected, analysis of HeLa-T4+ cells transfected with
this vector revealed that the introduced mutations
improved the efficiency of A7 as evident by a dramatic
increase in the amount of spliced transcript (Fig. 3A and
3B, cf. lane 1 with 2). This was also confirmed by in vitro
splicing experiments with the respective splicing con-
structs (data not shown). In the presence of Rev however,
almost no unspliced poly(A)+ message was observed (Fig.
3A, B, cf. lane 1' with 2'), suggesting that splicing,
enhanced by the strength of the 3'ss, competes with Rev
activity.
To address the question of whether a suboptimal 5'ss
could compensate for an efficient 3'ss in Rev function we
combined a 5'ss of intermediate complementarity to U1
snRNA (-1G3U, Fig. 2A) [28] with the efficient 3'ss A7+. In
agreement with our previous results, in the presence of A7
this intermediately strong 5'ss led to a 2–3 fold decrease
in the amount of RNA (Fig. 3A, cf. lanes 1 and 3, 1' and
3'). However, while the ratio of spliced to unspliced tran-
scripts (Fig. 3A, s/us) was altered only 3-fold, in the pres-
ence of A7+ this ratio increased up to 25-fold irrespective
of the strength of the 5'ss (Fig. 3). This finding demon-
strates that Rev activity is specifically and inversely
dependent on the efficiency of the 3'ss A7.
To determine the sequence requirements of a 3'ss compat-
ible with Rev function in more detail, we constructed a
single-intron splice reporter based on a truncated HIV-1
tat/rev intron harbouring the RRE (Fig. 4A) and analyzed
3'ss A5 because of its complexity. A5 exhibits a discontin-
uous pyrimidine stretch and overlaps with the competing
alternative 3'ss 4c, 4a and 4b. Moreover, ten BPSs have
been experimentally mapped in this region, five of which
are associated with splicing at 3'ss A5 [14,30] (see Fig. 5,
constructs A4cab and A5). Since the AG-dinucleotides and
BPSs can compete for binding of splicing factors we
mutated them consecutively (Fig. 4A): First the AG dinu-
cleotides of 3'ss A4c, a and b were changed to CG (AG-) to
exclude splicing at these positions. Next, the complemen-
tarity between the 5' BPS (named BPS1 in Fig. 4A) and U2
snRNA was reduced while the complementarity of the 3'
BPS (BPS2) was enhanced (b1- b2+). Thirdly, the pyrimi-
dine content was increased from 52% in the wild type 3'ss
A5 to 60% (Py+) and 72 % (Py++), respectively.
Following transient transfection of HeLa-T4+ cells with
these constructs the poly(A)+ RNA was analyzed by North-
ern blot. Neither the mutations of the upstream AGs (Fig.
4B, lane 2) nor of the branch sites (lane 3) led to splicing
at the 3'ss A5 but efficiently allowed Rev-dependent
detectability of the unspliced transcript (lanes 2' and 3').
Spliced RNA was not detected until the pyrimidine con-
tent was further increased (lane 4 and 5). Remarkably, a
pyrimidine content of 60% (Py+) was still compatible
with a low-level of Rev function (lane 4') but in contrast,
a highly efficient 3'ss due to a further increase in the pyri-
midine content of only 12% (Py++) was not (lane 5').
Removing the improvement of BPS2 (SA5 b1- AG- Py++)
reduced splicing efficiency 3-fold (cf. lane 5 with 6) and
concomitantly restored Rev-compatibility (cf. lanes 5' and
6') in spite of the high pyrimidine content. This suggests a
comprehensive effect of overall 3'ss strength on Rev activ-
ity.
Interestingly, we found no indication that the suboptimal
BPS 1 and BPS 2 were competing with each other. Splicing
was less efficient than in the construct with an optimal
branch site (cf. lane 7 with 5), but enhanced compared toRetrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
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the construct with only one predicted suboptimal branch
site (cf. lane 7 with 6). Reconstruction of the AGs of 3'ss
A4c, a, b further decreased the level of spliced transcripts
(cf. lane 7 with 8) but increased the level of the Rev-
dependent unspliced RNA (cf. lane 7' with 8'). In general,
the amount of unspliced transcript in the presence of Rev
(Fig. 4B and 4C, lanes 1'–8') was inversely proportional to
that of the spliced transcript. This confirms our findings
shown in Fig. 3, that splicing efficiency driven by the 3'ss
competes with Rev function.
Weakening of the 5'ss D4 does not compensate for the strength of 3'ss A7 Figure 3
Weakening of the 5'ss D4 does not compensate for the strength of 3'ss A7. HeLa-T4+ cells were transiently trans-
fected with the subgenomic HIV-1 constructs (SV E/X tat - rev -) combining an efficient (A7+) or inefficient (A7) 3'ss with a 5'ss 
with high (D4) or lower (-1G3U, cf. Fig. 2A) complementarity to U1 snRNA. The p(A)+ RNA was analyzed by Northern blot-
ting (cf. Fig. 2). (A) Northern blot with indication of the ratio of spliced (s) and unspliced (us) RNA in presence of Rev ([s/us], 
mean ± standard error) from three independent experiments. (B) Mean values of the relative amounts of spliced (s, black) and 
unspliced (us, grey) transcripts from three independent experiments, normalized to transcription efficiency (hGH). The spliced 
(s) and unspliceds (us) RNA populations were quantified from different exposure times of the blots to adjust for the different 
levels of signal intensities. The maximum values of both RNA populations were defined as 100%.
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The strength of the 3'ss competes with Rev responsiveness Figure 4
The strength of the 3'ss competes with Rev responsiveness. (A) Nucleotide sequence of one-intron constructs with 
mutations in the 3'ss A5. The reported branch point sequences for A5 (grey boxes, asterix indicates the branch point nucle-
otide), the 3'ss A4c, a, b, A5 (black boxes) and the PPT (hatched) are marked. Mutated nucleotides compared to the wild type 
are underlined. (B) Northern blot analyses of the p(A)+ RNA after transient transfection of HeLa-T4+ cells with one-intron 
constructs carrying SA5 mutations (cf. Fig.2). (C) Diagram of the hGH standardized relative amounts of spliced (left) and 
unspliced (right) transcripts from (B). The maximal amount was defined as 100%. The numbers below correspond to the lanes 
of the Northern blot.
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The intrinsic strengths of the HIV-1 splice acceptor sites 
differ largely
The observation that the efficiency of the 3'ss competes
with Rev function implicates that all HIV-1 3'ss should be
inefficient to allow the export of unspliced transcripts nec-
essary for virus replication. Indeed, this has been already
reported by O'Reilly and coworkers [27] however, at the
time of publication the knowledge of HIV-1 splice site reg-
ulation by cis-acting sequences was rather incomplete.
To differentiate between the contribution to the overall
splice site strength of the splice site regulating elements in
the 3' exonic sequences and the intrinsic strength of the
HIV-1 3'ss we used a splice site swapping strategy and ana-
lyzed the HIV-1 3'ss with or without their natural down-
stream exonic sequences (Aex and A, respectively, Fig. 5).
Each 3'ss included the experimentally defined or
assumed, by complementarity to U2 snRNA, branch point
sequence, the polypyrimidine tract and the AG dinucle-
otide. Because of their functional and spatial overlap the
3'ss A4c, a and b were experimentally considered as an
entity. The 3'ss A6, which is located in the tat/rev intron,
was not included in this analysis because its activity has
been described in isolate HIV HXB2 but not in HIV NL4/
3 which was used in this study [2,31]. As reference
sequences the non functional (A7-) and the efficient 3'ss
(A7+) mutants shown in Fig. 2 and 3 were also included.
Schematic drawing of the one-intron splicing reporter Figure 5
Schematic drawing of the one-intron splicing reporter. Diagram of the one-intron construct used for comparison of 
the HIV-1 3'ss by a splice site swapping strategy. SV40: SV40early promoter, pA: SV40 polyadenylation sequence. RRE: Rev 
response element. Fragments including the different 3'ss (grey boxes) and branch sites (dashed line: assumed from consensus; 
underlined: reported BP, numbers are referring to the associated 3'ss, BP A2 [15], BP 4cab and A5 [14,30], BP A7 [14]) were 
inserted into the cassette. The ISS has been described by [22]. The 3'extended versions of the splice acceptor constructs addi-
tionally include the downstream exon sequences with cis-acting splicing regulating sequences (M1, M2 [this report]; ESSV 
[16,64]; ESS2p [18]; ESE2/ESS2 [17,32,43,44,49]; GAR [23,28]; ESE3 [17,21,24,25,33,65]; ESS3a, b [17,21,24,33,66]; splicing 
silencer (light grey boxes); splicing enhancer (dark grey boxes)).
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Northern blot analyses of these constructs revealed that
only 3'ss A2 and A3 led to detection of significant
amounts of spliced mRNA in the absence of their natural
3' exonic sequences (Fig. 6A, lanes 2 and 3). Consistent
with the results shown in Fig. 3 and 4 these two constructs
showed the lowest number of unspliced transcripts in the
presence of Rev (Fig. 6A, cf. lanes 2' and 3' with 1', 4'–6').
Thus, these results indicate that 3'ss A2 and A3 are the
most efficient core 3'ss, here referred to as the intrinsic
efficiency of the 3'ss. For all other 3'ss the intrinsic effi-
ciency was low and significant amounts of unspliced mes-
sage could be detected in the presence of Rev.
Interestingly, the opposite picture was obtained for the
series of constructs where the downstream exonic
sequences were included (Fig. 6B and 6C). Compared to
their respective intrinsic efficiencies, splicing at A2 and A3
was decreased 3-fold and 1.5-fold in the presence of their
downstream exons (Fig. 6C, cf. A2 with A2ex and A3 with
A3ex). This is in accordance with the described ESS ele-
ments, consisting of three hnRNP A1 binding sites within
exon 3 [16], and hnRNP H and hnRNP A/B binding sites
within exon 4 [18,32]. Therefore, significant amounts of
Rev-dependent, unspliced messages are only detectable if
the intrinsic strength of these 3'ss is silenced by their
downstream exonic sequence (cf. Fig. 6A, lane 2' and 3'
with Fig. 6B, lane 2' and 3').
Since the alternative 3'ss A4c, A4a, A4b and A5 are all in
close proximity to each other we tested whether these sites
are regulated by the same bidirectional enhancer in exon
5 (A4cab5ex), which also leads to efficient splicing of the
flanking 3'ss A5 and 5'ss D4 [23]. Alternatively, additional
sequences upstream of this ESE may be sufficient to influ-
ence the strength of at least one of the 3'ss A4c, A4a and
A4b (A4cabex). The result showed that in the absence of
the bidirectional ESE in exon 5 none of these 3'ss could be
adequately activated as evident by the absence of any
spliced transcript (Fig. 6B, lane 4). Hence, the alternative
3'ss A4c, A4a, A4b and A5 seemed to be moderately acti-
vated by the same bidirectional enhancer in exon 5, still
allowing Rev-mediated nucleocytoplasmic transport of
unspliced transcripts (cf. Fig. 6B, lane 4' with lanes 5' and
6'). Comparison of the amount of spliced transcript from
the constructs carrying either the BPS of all 3'ss A4c, A4a,
A4b and A5 (Fig. 6C, A4cab5ex) or only the BPS for the
3'ss A4a, A4b and A5 (A5ex) showed a slight increase
(30%) in the amount of spliced transcript of the latter.
This suggests that competition of the four alternative 3'ss
might also contribute to the inefficiency of splicing and
that this is also supportive for the Rev-mediated export of
the unspliced message.
To date A7 is the only splice site with a known splicing
silencer in the intronic region and therefore we cannot
distinguish between the impact of the suboptimal PPT
and this ISS on the intrinsic inefficiency of this 3'ss (Fig.
6A, lane 6). However, splicing at A7 depends on activa-
tion by its flanking downstream sequences carrying the
bipartite ESE3/ESS3 regulatory sequence (cf. Fig. 6A lane
6 with Fig. 6B, lane 7) [17,21,25,33]. Thus, in this experi-
mental context, the ESE clearly dominates over the ESS
function.
Most strikingly, 3'ss A1 extended by its natural exonic
sequence turned out to be the most efficient 3'ss of all
(Fig. 6B, cf. lane 1 with 2–7). Even in the presence of Rev,
only a very small amount of unspliced message was
detected comparable to 3'ss A7+ (Fig. 6B, cf. lane 1' with
9'). Therefore, from these experimental results we con-
clude that exon 2 contains a strong splicing regulatory ele-
ment, which has not been identified so far.
These results combined show that, although all HIV-1 3'ss
are predicted to be weak on the basis of their intronic
sequences, there are distinct differences in their intrinsic
splicing efficiency. To co-ordinate both splicing and Rev
function the strength of the individual 3'ss is finally regu-
lated by cis-regulating ESEs and ESSs in their 3' exons.
An SF2/ASF-dependent splicing enhancer in exon 2
Quantification of the spliced transcripts from three inde-
pendent Northern blots in the presence and absence of
the downstream flanking exonic sequences revealed that
the exon 2 sequence improved splicing at the 3'ss A1
about 11-fold (Fig. 6C, cf. A1 and A1ex). A heptameric
motif TGGAAAG occurred twice within this relatively
short exon of only 50 nucleotides. Moreover, it is con-
served in the different strains of the HIV-1 group M (Fig.
7). Consistent with our observation that at least two SR-
binding sites are necessary for supporting U1 snRNA
binding at 5'ss D4 [34] (Freund and Schaal, unpublished
data) we examined whether these heptameric sequences
might constitute a bipartite ESE. Therefore, we generated
a two-intron minigene construct with exon 2 as the inter-
nal exon and mutated either heptamer 1 (M1) or hep-
tamer 2 (M2) (Fig. 8A). RT-PCR analysis of the transcripts
following transient transfection of HeLa-T4+ cells revealed
that mutating either of one of these heptamers totally
abolished exon 2 inclusion (Fig. 8B, cf. lane ex2 with Δ M1
and Δ M2). Thus, this heptameric motif most likely con-
stitutes a key element of an ESE in exon 2. Furthermore, it
confirms our hypothesis that at least two putative binding
sites are necessary to define a functional enhancer. Since
GAAAGGA was predicted to bind SF2/ASF by ESEfinder
[35] we analyzed SF2/ASF-binding by pull-down and sub-
sequent Western blot analysis using a polyclonal antibody
against SF2/ASF. As shown in Fig. 8C immunoblot analy-
sis of proteins from HeLa nuclear extracts pre-incubated
with either RNA of in vitro transcribed exon 2 or exon 2Retrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
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The strength of the 3'ss competes with Rev responsiveness Figure 6
The strength of the 3'ss competes with Rev responsiveness. (A) Northern blot analysis (cf. Fig. 2) from HeLa-T4+ cells 
transfected with constructs containing the HIV-1 3'ss in absence of their authentic 3' exon sequences. The particular 3'ss and 
the co-transfection of a rev expressing plasmid (SVcrev) are given above the lanes. The 3'ss A7- and A7+ were used as reference 
constructs for a nonfunctional and an efficient 3'ss. All lanes were derived from the same Northern blot. (B) Northern blot 
analysis from cells transfected with 3'ss in presence of their authentic 3' exon sequences (ex). All lanes were derived from the 
same blot. (C) Mean values of the relative amounts of spliced transcripts in absence and presence of the 3' exon sequences 
from three independent experiments, normalized to transcription efficiency (hGH, cf. Fig. 2). The amount of spliced transcripts 
derived from the construct containing the improved A7+ was defined as 100% (not shown).
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carrying mutations Δ M1 and Δ M2 revealed that the intro-
duced mutations led to reduced reactivity of a polyclonal
SF2/ASF antibody with a band of the corresponding
molecular mass of SF2/ASF-binding sites. To confirm the
SF2/ASF-dependent exon 2 recognition two additional
mutations were analyzed which were predicted by ESE-
finder to specifically abolish SF2/ASF-binding. As
expected these two constructs (Δ M1 SF2-, Δ M2 SF2-) led
to a complete lack of exon 2 recognition (Fig. 8B) support-
ing the observation that M1 and M2 represent the SF2/
ASF-dependent exon 2 splicing enhancer. Since we were
interested in analyzing this newly identified ESE within an
infectious molecular clone we set out to test for a silent
point mutation predicted to specifically inactivate this
enhancer. Based on computer analysis only one mutation
was found that fulfilled the desired criterion (Δ M1 – 43).
The mutation Δ M1 – 43 resulted in a slightly reduced loss
of exon 2 recognition compared to the other mutations
(Fig. 8B). The most obvious difference was the appearance
of a comparable amount of unspliced transcript. Never-
theless, this result confirmed that the Δ M1 – 43 mutation
affected exon 2 recognition.
Therefore, we inserted the Δ M1 – 43 mutation into the
molecular clone NL4/3 and investigated its effect on viral
replication in PM1 cells. Unexpectedly, no difference in
the replication kinetic was observed throughout the infec-
tion period of up to 10 days (data not shown) suggesting
that Δ M1 – 43 could not dramatically impair viral gene
expression. However, analyzing the viral mRNA of the
infected cells at day 5 post-infection by RT-PCR using
primers specific for the upstream region of the HIV-1
genome revealed a different splicing pattern for the non-
coding leading exons (Fig. 8A). As observed within the
splicing reporter, the presence of the Δ M1 – 43 mutation
led to a significant loss of exon 2 recognition (cf. band
1.2.4 in lanes NL4/3 and Δ M1-43) confirming that the
newly identified ESE within exon 2 supports exon defini-
tion within the context of the viral genome. Furthermore,
the lack of exon 2 recognition was accompanied by an
increase in exon 3 recognition (cf. band 1.3.4 in lanes
NL4/3 and Δ M1-43). These results support recent find-
ings that the optional leader exons might not play a direct
role in viral gene expression [36]. The most abundant
detectable spliced isoform corresponded to a 1.4 tran-
script which was not expected to be affected by the muta-
tion. However, most surprisingly, the amount of vif
mRNA was also not altered by the Δ M1 – 43 mutation (cf.
band 1.2l in lanes NL4/3 and Δ M1-43), demonstrating
that this mutation exclusively impaired exon 2 definition
but not intron (D1 – A2) definition. To confirm these
results functionally we compared the replication kinetics
of NL4/3 and NL4/3 Δ M1-43 in the vif non-permissive
and permissive cell lines CEM and CEM-SS respectively.
Consistent with the PM1 infection experiments no differ-
ence in the viral replication kinetics could be observed
between CEM and CEM-SS (data not shown) indicating
that the level of vif expression is not impaired by the Δ M1
– 43 mutation during the infectious experiment up to 16
days.
To further investigate the apparent discrepancy between
the transient transfection experiment using the splicing
reporter (cf. Fig. 8B, lane Δ M1-43) and the infection
experiments we specifically analyzed the effect of the Δ
M1 mutation on splice site usage of A1 in the splicing
reporter by excluding exon definition through deletion of
5'ss D2. Similar to the infection experiments 3'ss A1 usage
involving in intron definition still occurs in the presence
of Δ M1 mutation although to a somewhat lesser extent
(Fig. 9B, D2- Δ M1). In contrast, mutating both hepta-
meric sequences (Fig. 9B, cf. D2- Δ M1 with D2- Δ M1/2)
resulted in a total failure of 3'ss A1 recognition. Thus, the
intron-containing Rev-dependent vif  mRNA is less
dependent on the strength of the bipartite ESE (if defined
through the number of SR binding sites).
Discussion
Previous mutational analyses of HIV 5'ss D4 revealed that
its splice function was inessential for Rev function but that
increased binding of U1 snRNA to this region correlates
with increased steady state levels of spliced as well as
intron-containing subgenomic HIV-1 transcripts
[28,37,38]. Therefore, we investigated the specific influ-
ence of the HIV-1 3'ss on RNA steady state levels and Rev
responsiveness. In a subgenomic env construct we found
that inactivation of 3'ss A7 and the upstream cryptic sites
A7a and A7b totally abolished splicing of the tat/rev
intron, without affecting the number of unspliced Rev-
dependent transcripts. Thus, Rev function requires neither
a splicing-competent 5' nor 3'ss. This is in accordance with
earlier findings that Rev can act independently from splic-
ing provided that U1 snRNA can bind the env RNA to pro-
tect it from degradation [39,40]. It also confirms that
stabilization of the HIV-1 RNA upon U1 snRNA binding
to the 5'ss is independent of late spliceosome formation.
On the other hand an increase in 3'ss A7 splicing effi-
ciency (inferred from a greater amount of detectable
spliced mRNA in the absence of Rev), corresponded with
decreased amounts of unspliced Rev-dependent mRNAs.
Consistent with this, the rate limiting step determining
the kinetic of the splicing reaction seems predominantly
determined by the strength of 3'ss. This determines the
use of the pre-mRNAs as a splicing substrate or as a target
for Rev-dependent nuclear export. This model is sup-
ported by the finding that slightly reducing the strength of
the 5'ss only led to moderate differences in the ratio of
spliced versus unspliced subgenomic transcripts while
mutating the 3'ss altered the ratio at least 10-fold (Fig.
3A).Retrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
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Efficient 3'ss compete with Rev function but retroviral rep-
lication requires an equilibrium between splicing and
nuclear export of intron-containing transcripts and there-
fore the low efficiency of the 3'ss is a key factor for viral
replication. Under such suboptimal conditions a slow
down of the first transesterification reaction is likely
[14,41,42]. Nevertheless, a prediction of 3'ss efficiency
based only on the evaluation of the sequence by available
algorithms is still not reliable in all cases due to the com-
plex interplay of the U snRNAs and proteins involved in
3'ss recognition. An experimental assessment of the splic-
ing efficiency of the HIV-1 3'ss was performed by O'Reilly
and coworkers [27]. In a heterologous β-globin/HIV-1
construct they evaluated the relative efficiencies of the
HIV-1 3'ss compared to the β-globin 3'ss A1 which was
used as a reference for an efficient 3'ss. The outcome of
this study was a relative homologous clustering of the
HIV-1 3'ss between 40% and 60% splicing efficiency with
exception of 3'ss A1 (in the original publication referred
to as 3'ss A2, see also Fig. 1) which showed a significantly
lower efficiency (26%). Unfortunately, at that time the
relevance and multitude of cis-acting sequences regulating
alternative splicing in the HIV-1 transcripts are just start-
ing to be unfolded. Therefore, only the downstream
exonic cis-acting sequence involved in regulation of 3'ss
A7 [21,33] was completely included in the investigated
fragment (101 nt 3' of the intron/exon border). However,
in the past, it had become evident that trans-acting factors
are involved in constitutive as well as alternative splicing
and that almost all HIV-1 exons and also some intron
sequences include splicing enhancers and/or silencers
[16-18,21-23,28,33,43,44] (see Fig. 1, for recent reviews
see [5,45]. Hence, from this apparent ubiquitous presence
of cis-acting sequences the question arose as to how the
classical elements defining a canonical splice site (BPS,
PPT, AG-dinucleotide) and the cis-acting elements con-
tribute to the overall strength of the different HIV-1 3'ss
and their response to Rev. To evaluate the impact on the
intrinsic strength of the 3'ss, i.e., the intronic sequence
versus the cis-acting, exon-located enhancer and silencer
elements, we compared the efficiency of the HIV-1 3'ss A1,
2, 3, 4cab and 5 in the presence and absence of their nat-
ural downstream exonic sequences in a splice site swap-
ping strategy.
Our comparison of the HIV-1 3'ss with an optimized 3'ss
as an internal reference with almost no response to Rev,
revealed significant variation in the strength of the viral
3'ss with relative splicing efficiencies from 1% to 52% in
the absence and 15% to 106% in the presence of their nat-
ural 3' sequences. Based on these data we grouped the
HIV-1 3'ss into two different categories. The first category
includes 3'ss A1, A4cab, A5 and A7 which were all but
inactive in the absence of their 3' exonic sequences. Their
3' sequences had an overall stimulatory effect on splicing
efficiency at these sites. This is especially interesting for
the increase in splicing efficiency at A7 (from 4 to 57%)
since this 3' exon includes both a splicing enhancer and a
silencer [21,25,43] that has been shown to compete with
ASF/SF2-binding at the ESE and hnRNPA1 binding at the
ESS [24,26,46]. Thus, different ratios of ASF/SF2 and
hnRNP A1 in different cells may lead to differences in the
activation of A7. Under our experimental conditions,
however, a dramatic influence of the ESS on the strength
of A7 was not detectable (data not shown). Hence, the
ESE was clearly dominant over the ESS function. Addi-
tionally, we identified a new cis-acting sequence within
exon 2, which profoundly increased splicing efficiency at
Alignment of exon 2 of HIV-1 M group consensus sequences Figure 7
Alignment of exon 2 of HIV-1 M group consensus sequences. Exon 2 sequences were obtained from the HIV Sequence 
Database [67] flanked by A1 and D2. The heptameric sequences (M1 and M2) found to enhance splicing are highlighted by grey 
boxes.
CON OF CONS gGACAGCAGA GAcCCaaTTT GGAAaGGACC aGCaaaaCTa CTcTGGAAAG
M group ---------- ---------- ---------- ---------- ----------
CONSENSUS A1 ---------- --t------- ---------- ---------- ----------
CONSENSUS A2 ---------- --T------- ---------- ---------C --t-------
CONSENSUS B ---------- --t---c--- ---------- ------g--t ----------
CONSENSUS C a--------- -----t---- ---------- ---c------ ----------
CONSENSUS D ---------- --T------- ---------- ------G--t ----------
CONSENSUS F1 ---------- ------G--- ---------- ------G--- ----------
CONSENSUS F2 ---------- ------g--- ---------- ------g--- ----------
CONSENSUS G ---------- ---------- ---------- ---------- ----------
CONSENSUS H ---------- ---------- ---------- ---------c ----------
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An ASF/SF2-dependent ESE within exon 2 Figure 8
An ASF/SF2-dependent ESE within exon 2. (A) Sequence of exon 2 (top line) and analyzed mutations. The heptameric 
sequences (M1 and M2) of the bipartite ESE are boxed and the mutations are given below exon 2 sequence. A schematic draw-
ing of the two-intron minigene with exon 2 as internal exon flanked by A1 and D2 is given below the sequences. (B) HeLa-T4+ 
cells were transfected with LTR ds ex2 (ex2) or its mutations (cf. (A)), cotransfected with SVctat and pXGH5 (hGH) and ana-
lyzed by RT-PCR as described in Materials and Methods. (C) Pull-down analysis of in vitro transcripts of either exon 2 or exon 
2 carrying both mutations, M1 and M2 in HeLa cell nuclear extract. The immunoblot was detected with a polyclonal SF2/ASF 
antibody.
Exon 2 GGACAGCAGAGATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAG
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3'ss A1. This regulatory element includes two TGGAAAG
heptameric sequences which constitute key elements of a
bipartite ESE and support our observation that a func-
tional enhancer seems to be defined by at least two indi-
vidual binding sites [34]. The identification of ASF/SF2 as
the respective splicing regulatory protein is in agreement
with the finding, that overexpression of ASF/SF2 stimu-
lated splicing at site A1 in HIV-1 pNL4/3 transfected 293T
cells [47].
The second group of 3'ss, A2 and A3, showed approxi-
mately 50% splicing efficiency in the absence of exon
sequences and a 2–3 fold decrease in efficiency in the
presence of exon sequences, consistent with published
ESS sequences in exon 3 (ESSV) and 4 (ESS2p, ESS2) (see
Fig. 1) [16-18,43,48]. Despite the presence of these ESSs
usage of both 3'ss could also be stimulated in vivo follow-
ing overexpression of ASF/SF2 [47] and in vitro upon addi-
tion of recombinant SC35 [49] disclosing the
ambivalence of HIV-1 3'ss regulation. A reason for the
restrictive control of 3'ss A2 and A3 might be the cytotox-
icity of Tat [50] and Vpr [51] which are translated as first
reading frames of the appropriate mRNAs.
Comparing the two splice site groups we noticed that the
pyrimidine content of the PPT was highest in 3'ss A2 and
A3 (65 and 69%) and lower in the other 3'ss (40% up to
max. 62%). This encouraged us to analyze the contribu-
tion of the intronic sequence elements, i.e., BPS, PPT and
the AG-dinucleotide, to the efficiency of the HIV-1 3'ss. To
this end, taking the A5 sequence as an example, we
increased the pyrimidine content stepwise from 52/55%
in the wild-type sequence to 60% (Py+) and 72% (Py++)
and combined it with an improved complementarity of
the branch site to U2 snRNA and removal of competing
AG dinucleotides A4c, a, b (Fig. 4). Simultaneous
improvement of these elements led to enhanced splicing
at A5 with no response to Rev. Moreover, if only one of
the elements was altered exclusively the increase of the
pyrimidine content to 72% but not to 60% led to
enhanced splicing at A5 (data not shown). The altered
branch point and removed AGs were only able to increase
Mutation of M1 by a single, silent point mutation does not alter vif mRNA expression within an infectious molecular clone Figure 9
Mutation of M1 by a single, silent point mutation does not alter vif mRNA expression within an infectious 
molecular clone. HIV-1 splicing pattern of PM1 cells infected with NL4/3 or NL4/3 carrying a silent point mutation within M1 
(ΔM1-43, cf. Fig. 8A). The upper part shows an RT-PCR amplification for the vif 1.2I mRNA (the letter I denotes incompletely 
spliced or intron-containing mRNA) using primer pair #1544/#2183. The middle part was obtained using primer pair #1544/
#1542. The stars indicate that these bands were isolated from the gel and confirmed by sequencing. To compare the total 
amount of HIV-1 transcripts within both mRNA preparations a separate RT-PCR was performed using primer pair #2335/
#480 amplifying exon 1 sequence. (B) RT-PCR analysis of RNA from HeLa-T4+ cells transfected with the minigene lacking D2 
(cf. figure legend 8B).
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splicing in the presence of 60% or more pyrimidines.
These findings show that the differences in the pyrimidine
content of the HIV-1 3'ss only as a first approximation
could explain their different splicing efficiencies.
As previously determined experimentally for all HIV-1 5'ss
[28,29] and here for all HIV-1 3'ss, there is no strict alter-
nation between strong 5'ss and weak 3'ss as discussed
recently [52]. On the contrary, D1 and A1 are the most
efficient splice sites defining the first intron. Nevertheless,
this splice site pair is not the most frequently recognized
pair (based on the frequencies of only 16% exon 2 inclu-
sion and 1% vif mRNA, Fig. 10B) most likely due to the
intrinsically weakest 5'ss D2 which opposes cross-talk of
the splice site pair across exon 2. This suggests that,
although harboring a bipartite ESE HIV-1 exon 2 will be
efficiently included only if the intrinsic strength of D2 is
increased. Indeed, this has been shown most recently
resulting in decreased virus production [36]. However,
our finding that a switch in splice site pair recognition can
crucially depend on exonic cis-acting regulatory sequences
supports the possibility that Rev by interacting with trans-
acting splicing regulatory proteins could switch cross-talk
of splices site pairs. Alternatively, by interacting with trans-
acting splicing regulatory proteins, Rev could functionally
substitute for an ESE. Consistent with this, Rev has been
found to bridge p32 which co-purifies with ASF/SF2 to the
RRE thereby possibly stabilizing the interaction of U1
snRNP with the 5'ss and arresting further spliceosome for-
mation [53]. This model provides an explanation for our
finding that partially inactivating the ESE (Δ M1 – 43
mutation) did not affect processing of the Rev-dependent
1.2I vif mRNA but specifically leads to loss of exon 2 rec-
ognition within the Rev-independent class of mRNAs.
Although it seems that HIV-1 splice site regulation is
highly complex as outlined here (without even addressing
the possible impact of secondary structures or superordi-
nated hairpin structures on splice sites usage [54,55]) it is
this complexity that provides a possibility to selectively
inhibit HIV-1 splice site usage as a potential treatment
strategy without cellular side effects [56,57].
Methods
Oligonucleotides
Oligonucleotides were synthesized and purified as previ-
ously described [58]. Sequences are given in Tab. 1.
Recombinant plasmids
SVcrev was constructed by cloning the EcoRI-XhoI frag-
ment from pUHcrev [59] into pSVT7. The SV40 early env
expression vector SV E/X tat- rev- contains the EcoRI-XhoI
fragment of pNLA1 [60], a cDNA derivative of pNL4/3.
The 5' ss mutations were constructed as previously
described [28]. To introduce the mutations A7- and A7+ in
3'ss A7, overlapping oligos were PCR amplified (A7-:
#626, #628; A7+: #797, #798), the PCR products were
restricted with AvaI/AflII (A7-) and SpeI/XmaI (A7+),
respectively, and cloned into the appropriate vector back-
bones.
The one-intron constructs (SV-SD/RRE/SA-pA) and muta-
tions in the 5'ss were constructed as previously described
[28]. Mutations in the 3'ss were introduced by swapping
the  BstEII-XmaI fragment except for A7ex which was
cloned as a BstEII-BamHI fragment. For A7+ overlapping
oligos (#796/#797) were amplified. For A7 - a fragment
was amplified using primer pair #985/#986 and plasmid
SV E/X tat -rev - SA7 - as template. HIV 1 3'ss A1 sequence
was amplified using pNL-gpt (kindly provided by Valerie
Bosch, ATV-DKFZ Heidelberg) as template both with 5'
primer #948 and 3' primer either #947 (A1) or #1089
(A1ex). All other HIV 3' ss were amplified using pNLA1 as
template and primers #946 and either #945 (A2) or
#1091 (A2ex), #936 and #939 (A3) or #1492 (A3ex),
#940 and #941 (A4cab) or #943 (A4cab5) or #1088
(A4cab5ex), #942 and #943 (A5) or #1088 (A5ex), #800
and #1065 (A7) or #139 (A7ex). The A5 mutations were
constructed by introducing PCR products from overlap-
ping oligos (A5 AG -: #1591, #1483; A5 b1-b2+AG  -:
#1586, #1484; A5 b1-b2+AG -Py+: #1586, #1592; A5 b1-
b2+AG  -Py++: #1586, #1587; A5 b1-AG  -Py++: #1482,
#1389; A5 AG -Py++: #1388, #1590). For A5 Py++ (#942,
#1481) and A5 Py+ (#942, #1486) pNLA1 was used as a
PCR template.
To clone the three-exon-two-intron minigene reporter
construct LTR ds ex2 two PCR fragments containing a 5'ss
(#377, #918; BssHII-SalI) and a 3'ss (#931, #932; PstI-
SalI) were inserted into LTR 1.4tatCAT, a vector coding for
transcripts with the native HIV-1 tat 1.4 mRNA leader
sequence [61], to generate LTR SD SA tatCAT.
Exon 2 including flanking intronic sequences of pNL-gpt
was PCR-amplified with primers #1183 and #1913 and
cloned into LTR SD SA tatCAT via EcoRI and PstI. Simi-
larly, to insert the mutations of heptamer 1 and 2 the 3'
PCR primer was substituted for #1913a (LTR ds ex2
hept.1) and #1913b (LTR ds ex2 hept.2) respectively.
All plasmid sequences can be obtained on request.
Cell culture, transfection and Northern blot analysis
HeLa-T4+ cells [62] were transfected with FuGENE™ 6
(Roche Molecular Biochemicals) and total RNA was pre-
pared 30 h after transfection by a modified guanidinium
isothiocyanate protocol [63] using RNA-clean (Hybaid-
AGS, Heidelberg). The poly(A)+ RNA from 80–100 μg
total RNA was isolated with Dynabeads®  oligo(dT)25
(Dynal, Oslo), subjected to electrophoresis on a 1.2% aga-Retrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
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rose-1% formaldehyde-gel, and blotted onto a positively
charged nylon membrane (Roche Molecular Biochemi-
cals). After UV crosslinking (0.5 J/cm2), the membrane
was hybridized with digoxigenin-(DIG) labeled antisense
RNA probes in a buffer containing 50% (v/v) formamide,
5 × SSC, 50 mM sodium phosphate (pH 7), 0.1% (w/v) N-
lauroylsarcosine, 7% (w/v) SDS, 2% (w/v) blocking rea-
gent (Roche Molecular Biochemicals), 50 mg yeast RNA/L
at 68°C. To monitor transfection efficiency and RNA
loading, the membrane was hybridized with a DIG-
labeled antisense RNA probe specific for exon 5 of human
growth hormone (hGH, expressed from cotransfected
plasmid pXGH5 as a transfection control). HIV-specific
RNA was detected by a DIG-labeled antisense RNA probe
specific for the 3' end of env (LTRcenvpA-, nt 8648–8887)
and detection with anti-Digoxigenin-AP-Fab fragments
(50 mU/ml; Roche Molecular Biochemicals) and chemi-
luminescence substrate (250 μM CDP-Star™; Roche
Molecular Biochemicals) as previously described [28].
Quantification was done with the Lumi-Imager F1 (Roche
Molecular Biochemicals) and the LumiAnalyst™ 3.1 soft-
ware.
RT-PCR assay
Isolation of total RNA was performed using a modified
guanidinium isothiocyanate protocol [63]. Cells were
washed twice with 2 ml of PBS and cell lysis was per-
formed with 500 μl of buffer D [4 M guanidinium-isothi-
ocyanat, 25 mM Na-Citrat pH 7, 0,5% N-Laurylsarkosin];
7.6 μl of 2-mercaptoethanol, 50 μl of 3 M sodium acetate
(pH 4), 500 μl of phenol and 100 μl of a chloroform-iso-
amyl alcohol mixture (24:1) were added and mixed for 15
s. After incubation on ice for 15 min, phases were seper-
ated by centrifugation (10,600 × g, 4°C, 20 min). RNA
was precipitated in 1 volume of isopropanol overnight.
After centrifugation (10,600 × g, 4°C, 20 min) the RNA
pellet was washed twice with 70% ethanol and dissolved
in 10 μl of DMDC-ddH2O. Prior to reverse transcription,
4 μl of RNA samples were subjected to DNase I digestion
using 10U DNase I (Roche Molecular Biochemicals) with
Schematic overview of HIV-1 splice sites and their strength Figure 10
Schematic overview of HIV-1 splice sites and their strength. (A) Schematic drawing of the HIV-1 pre-mRNA and the 
distribution of the splice sites. The relative strength of the splice sites, based on splice site swapping strategies in this and pre-
vious publications [27,29], is represented by the size of the letters. D5 and A6 (grey) are marked for better orientation but 
they are not used in HIV-1 NL4/3 and therefore their relative strength was not tested. D1A and A1A are recently published 
splice sites preferentially involved in RNA stabilization [6]. ESEs (hatched) and ESS/ISS (black) are marked. (B) Schematic draw-
ing of the exon structure in the 1.8 kb and 4 kb HIV-1 RNA classes. The numbers represent the relative incidence of exon 
inclusion [%] calculated from previously published RT-PCR analyses [2]. Differences to 100% in the total amount of the possi-
bilities of overlapping exon recognition are due to rounding errors. The darker the colour of the exons the more efficiently 
they are included in the alternatively spliced HIV-1 transcripts.
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Table 1: Oligonucleotides used throughout these experiments
Oligo no. sequence
#139 5'-CCCAAGCTTTCTAGACTCGAGCTACAAAATCCTTTC
#377 5'-CTGAAGCGCGCACGGCAAGAGGCGAGGGGAGGCGACTG
#480 5'-GCGCGCTTCAGCAAGC
#481 5'-GCGCGCACGGCAAGA
#559 5'-CTTTACGATGCCATTGGGA
#626 5'-TGTCTTAAGTATAGTGAATCGCGTTCGCCAAGGATACTCACCA
#628 5'-CCCCTCGGGATTGGGAGGTGGGTTTGGAAGCTTAGTGGTGAGTATCC
#796 5'-TGAGGTTACCGTTCTTTCTATT
#797 5'-
GATCCCGGGATCCTCGGGATTGGGAGGTGGGTCTGAAAAGAAAGAGGAGAATAACCTTGACGAACACGGTTAGCAAT
AGAAAGAAC
#798 5'-TGAACTAGTAGGTTTAAGAATAGTTTTTGCTGTTCTTTCTATT
#800 5'-TGAGGTTACCGTACTTTCTATAGTGAAT
#918 5'-GCTATGTCGACAAGGAGCTGCAGATCGATGAATTCGATACTTACCAGTCGCCTCCCCTC
#931 5'-GCTATGTCGACACCCAATTCTGAAACGATAATGGTGAATATCCCTGCCTAACTCTATTCACTATA
#932 5'-ATCCTGCAGAATAGTTTTTGCTGTACTTTCTATAGTGA
#936 5'-ACTGGTTACCACATATCTATGAAACT
#939 5'-ACAGGATCCATCCCCGGGCTGAAATGGATAAACA
#940 5'-ACTGGTTACCTGTACCAATTGCTATT
#941 5'-ACAGGATCCATCCCCGGGCTAAGGCTTTTGTCAT
#942 5'-ACTGGTTACCAAAAAGTGTTGCTTTC
#943 5'-ACAGGATCCATCCCCGGGCTGCCATAGGAGATGC
#945 5'-ACAGGATCCATCCCCGGGCTGAAAAACAGTCAAA
#946 5'-ACTGGTTACCACCCTGAATTAGCAGA
#947 5'-ACAGGATCCATCCCCGGGCTGTAATAAACCCGAA
#948 5'-ACTGGTTACCTAGCAACAGACATACA
#985 5'-GATGGATCCCGGGCTCGGGATTGGGAG
#986 5'-TGAGGTTACCGTCTTAAGTATA
#1065 5'-ATCCCCGGGCTGAAACGATAATGGTGA
#1088 5'-ACAGGATCCATCCCCGGGTGCTTTGATAGAGAAG
#1089 5'-ACAGGATCCATCCCCGGGCTTTCCAGAGGAGCTT
#1091 5'-ACAGGATCCATCCCCGGGCTTGTTATGTCCTGCT
#1183 5'-CTAGAATTCAGCAACAGACATACA
#1224 5'-TCTTCCAGCCTCCCATCAGCGTTTGG
#1225 5'-CAACAGAAATCCAACCTAGAGCTGCT
#1388 5'-TGAGGTTACCAAAAAGTGTTGCTTTCATTGCCACGTTTGTTTCATGAC
#1389 5'-ATCCCCGGGCTGAAAGAGGAGAAGGCGAGGGCGTTTGTCATGAAAC
#1481 5'-ATCCCCGGGCTGAAAGAGGAGAAGGCTAGGGCTTTTGTCATGAAAC
#1482 5'-TGAGGTTACCAAAAAGTGTGGCGTCCGTTGCCACGTTTGTTTCATGAC
#1483 5'-ATCCCCGGGCTGCCATAGGAGATGCCGAAGGCGTTTGTCATGAAAC
#1484 5'-ATCCCCGGGCTGCCATAGGAGATGCCGAAGGCGTTTGTTAGTAAAC
#1486 5'-ATCCCCGGGCTGAAATAGGAGATGCCTAAGGCTTTTGTCATGAAAC
#1492 5'-ACAGGATCCATCCCCGGGAGGGCTCTAGTCTAGG
#1542 5'-CACCTTCTTCTTCTATTCCTT
#1544 5'-CTTGAAAGCGAAAGTAAAGC
#1586 5'-TGAGGTTACCAAAAAGTGTGGCGTCCGTTGCCACGTTTGTTTACTAAC
#1587 5'-ATCCCCGGGCTGAAAGAGGAGAAGGCGAGGGCGTTTGTTAGTAAAC
#1590 5'-ATCCCCGGGCTGAAAGAGGAGAAGGCGAGGGCGTTTGTCATGAAAC
#1591 5'-TGAGGTTACCAAAAAGTGTTGCTTTCATTGCCACGTTTGTTTCATGAC
#1592 5'-ATCCCCGGGCTGAAATAGGAGATGCCGAAGGCGTTTGTTAGTAAAC
#1913 5'-TACTGCAGTACTTTTATGTCACTATTATCTTGTATTACTACTGCCCCTTCACCTTTCCAGAGGAGCTTTGCTG
#1913a 5'-
CTACTGCAGTACTTTTATGTCACTATTATCTTGTATTACTACTGCCCCTTCACCTTTCCAGAGGAGCTTTGCTGGTCGA
TAGCAAACTGGATCTCTG
#1913b 5'-CTACTGCAGTACTTTTATGTCACTATTATCTTGTATTACTACTGCCCCTTCACGATAGCAGAGGAGCTTTGCTG
#2183 5'-GGTCAGGGTCTACTTGTGTGC
#2335 5'-GGGTCTCTCTGGTTAGACCAGRetrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
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50 mM Tris (pH 7.5) and 10 mM MgCl2 in a total volume
of 10 μl at room temperature for 1 h. After DNase I inac-
tivation at 80°C for 10 min, 4.5 μl of the DNase digested
RNA samples were reversed transcribed with 200U Super-
Script III RNase H-Reverse Transcriptase (Invitrogen)
according to the manufacturer's protocol using 0.375 mM
oligo(dT)15 (Roche Molecular Biocemicals) or 0.02 μM
sequence-specific oligo #1542 as primer. As a negative
control for the remaining plasmid DNA contamination of
each sample, a second assay was performed as described
above but replacing reverse transcriptase with ddH2O.
PCR was carried out with 1.25U AmpliTaq (Applied Bio-
systems) in a total volume of 50 μl according to the man-
ufacturer' protocol in a Robocycler Gradient 96
Temperature Cycler (Stratagene). All primers were used at
a final concentration of 0.2 μM. Spliced and skipped RNA
was detected with the primer pair #1544/#1542 and hGH
mRNA with primer pair #1225/#1224. Prior to PCR the
cDNA reaction mixture was denatured at 94°C for 3 min.
To determine the linear PCR-amplification range allowing
a semi-quantitative estimation of the relative abundance
of pSV-1-env and hGH mRNA, a preliminary PCR test
series was carried out using the same cDNA sample but
varying the PCR cycle numbers between 15 and 30 [94°C,
0.5 min; 52°C (pSV-1-env) and 56°C (hGH), respec-
tively, 1 min; 72°C, 1 min]. The reactions were completed
with a final elongation step of premature amplified prod-
ucts at 72°C for 10 min. Accordingly to the obtained
results, PCR analysis was performed with 26 cycles for
pSV-1-env as well as hGH PCR amplification.
PCR products were separated on 6% non-denaturating
polyacrylamide gels, stained with ethidium bromide (10
min) and visualized with the Lumi-Imager F1 (Roche
Molecular Biochemicals).
Pull-down Assay of ASF/SF2
Periodat-labeled in vitro transcripts (1 nmol) of Eco47lII-
linearized T7 Ex2 and T7 Ex2 Δ M1/Δ M2 plasmids carry-
ing mutations of the heptameric motive were prepared
using T7-MEGAshortscript™ (Ambion) and 0.1 M sodium
m-periodat. The binding reaction to the adipic acid dihy-
drazide agarose (Sigma) was performed over night in 0.1
M NaOAc pH 5.0. Complex formation was performed in
a 650 μl reaction volume containing 500 μl of HeLa
nuclear extract (Cell Culture Center, Belgium) and 150 μl
buffer D (20 mM HEPES-KOH pH 7.9, 100 mM KCl, 20%
glycerol, 0.2 mM EDTA, 0.5 mM DTT) by incubation at
30°C for 30 min. After washing five times in 1 ml of buffer
D the complexed RNAs were eluted by incubating the
beads in 60 μl of 2 × sample buffer, heating at 90°C for 10
min, followed by fractionation on an 7% denaturing poly-
acrylamide gel. The proteins were blotted onto a PVDF
membrane (Immobilon™ P, pore size 0.45 μm; Millipore)
by electroblotting with 70V in transfer buffer (200 mM
glycine, 25 mM Tris, 20% methanol) for 1 h. Blots were
blocked o/n in PBS with 10% bovine serum albumin
(BSA), 10% Tween®-20. Protein detection was performed
in PBS, 1% BSA, 1% Tween®-20, with a goat polyclonal
antibody raised against a peptide mapping near the C-ter-
minus of SF2/ASF of human origin (Santa Cruz Biotech-
nology, Inc. C-19:sc-10255) for 1 h, washed three times,
incubated with a horseradish peroxidase conjugated
AffiniPure donkey anti-goat IgG (Jackson ImmunoRe-
search Laboratories, Inc. #705-035-147), washed four
times, rinsed with water and visualized by a chemilumi-
nescence detection system (ECL™-system and ECL™ hyper-
film, Amersham; Super Signal® ultra, Pierce).
HIV-1 infection experiments
Cell cultures were maintained in RPMI 1640 medium
containing 10% fetal calf serum (Pansystems GmbH) and
antibiotics (penicillin and streptomycin). Viral stocks
were prepared by transfecting 293T cells with provirus
expression vectors, followed by ELISA (Innotest HIV p24
Antigen mAb; Innogenetics N. V.) of culture supernatants
for p24 content. For HIV-1 infection, 5 × 106 PM1, CEM
or CEM-SS cells were resuspended in 500 μl culture
medium and incubated at 37°C for 3 hours with 100 ng
of each HIV-1 viral stock (HIV-1 NL4/3 wild type and
ΔM1-43). After infection, cells were washed twice with
PBS without Ca2+ and Mg2+ and further cultured in 5 ml
medium for another 5 days. Subsequently, total RNA was
isolated using Trizol reagent according to the protocol of
the manufacturer (Invitrogen).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SK and MO performed the cloning work. Northern blot
analyses were carried out by SK, RT-PCR and pull-down
by MO. All infectious experiment were designed and con-
ducted in a P3 facility by IH and JH. JK conceived optimi-
zation of A7. HS devised and coordinated the study. SK
and HS drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank Klaus Strebel and Malcolm Martin for providing plasmid pNLA1, 
Valerie Bosch for pNL-gpt, the former members of our lab Martina Rath, 
Cordula Homberg and Jörg Krummheuer for plasmids SV tat- rev- E/X SA7-
, SV tat- rev- E/X SA7+ and LTR SD SA tatCAT, Richard Axel for providing 
HeLa-T4+ cells, and Imke Meyer for excellent technical assistance. We are 
also grateful to Alan Cochrane, Colin Mackenzie and the members of our 
lab Linda Hartmann and Corinna Asang for their critical comments on this 
manuscript. This work was supported by grants from the DFG HA 2580/2-
1 (J.H.) and SCHA 909/1-3 (H.S.), the Stiftung für AIDS-Forschung, Düssel-Retrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
Page 19 of 20
(page number not for citation purposes)
dorf (H.S.) and the Graduiertenförderung NRW by the Heinrich-Heine-
Universität, Düsseldorf (S.K.).
References
1. Furtado MR, Balachandran R, Gupta P, Wolinsky SM: Analysis of
alternatively spliced human immunodeficiency virus type-1
mRNA species, one of which encodes a novel tat-env fusion
protein.  Virology 1991, 185:258-270.
2. Purcell DF, Martin MA: Alternative splicing of human immuno-
deficiency virus type 1 mRNA modulates viral protein
expression, replication, and infectivity.  J Virol 1993,
67:6365-6378.
3. Robert Guroff M, Popovic M, Gartner S, Markham P, Gallo RC, Reitz
MS: Structure and expression of tat-, rev-, and nef-specific
transcripts of human immunodeficiency virus type 1 in
infected lymphocytes and macrophages.  J Virol 1990,
64:3391-3398.
4. Schwartz S, Felber BK, Benko DM, Fenyo EM, Pavlakis GN: Cloning
and functional analysis of multiply spliced mRNA species of
human immunodeficiency virus type 1.  J Virol 1990,
64:2519-2529.
5. Stoltzfus CM, Madsen JM: Role of viral splicing elements and cel-
lular RNA binding proteins in regulation of HIV-1 alternative
RNA splicing.  Curr HIV Res 2006, 4:43-55.
6. Lutzelberger M, Sinnathamby RL, Das AT, Berkhout B, Kjems J: A
novel splice donor site in the GAG-POL gene is required for
HIV-1 RNA stability.  J Biol Chem 2006, 281:18644-18651.
7. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M,
Nishida E: CRM1 is responsible for intracellular transport
mediated by the nuclear export signal.  Nature 1997,
390:308-311.
8. Fornerod M, Ohno M, Yoshida M, Mattaj IW: CRM1 is an export
receptor for leucine-rich nuclear export signals [see com-
ments].  Cell 1997, 90:1051-1060.
9. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, Haseltine WA:
Intragenic cis-acting art gene-responsive sequences of the
human immunodeficiency virus.  Proc Natl Acad Sci U S A 1988,
85:2071-2075.
10. Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis
GN:  Mutational inactivation of an inhibitory sequence in
human immunodeficiency virus type 1 results in Rev-inde-
pendent gag expression.  J Virol 1992, 66:7176-7182.
11. Mikaelian I, Krieg M, Gait MJ, Karn J: Interactions of INS (CRS)
elements and the splicing machinery regulate the produc-
tion of Rev-responsive mRNAs.  J Mol Biol 1996, 257:246-264.
12. Chang DD, Sharp PA: Regulation by HIV Rev depends upon rec-
ognition of splice sites.  Cell 1989, 59:789-795.
13. Stutz F, Rosbash M: A functional interaction between Rev and
yeast pre-mRNA is related to splicing complex formation.
EMBO J 1994, 13:4096-4104.
14. Dyhr-Mikkelsen H, Kjems J: Inefficient spliceosome assembly
and abnormal branch site selection in splicing of an HIV-1
transcript in vitro.  J Biol Chem 1995, 270:24060-24066.
15. Damier L, Domenjoud L, Branlant C: The D1-A2 and D2-A2 pairs
of splice sites from human immunodeficiency virus type 1
are highly efficient in vitro, in spite of an unusual branch site.
Biochem Biophys Res Commun 1997, 237:182-187.
16. Bilodeau PS, Domsic JK, Mayeda A, Krainer AR, Stoltzfus CM: RNA
Splicing at Human Immunodeficiency Virus Type 1 3' Splice
Site A2 Is Regulated by Binding of hnRNP A/B Proteins to an
Exonic Splicing Silencer Element.  J Virol 2001, 75:8487-8497.
17. Amendt BA, Si ZH, Stoltzfus CM: Presence of exon splicing
silencers within human immunodeficiency virus type 1 tat
exon 2 and tat-rev exon 3: evidence for inhibition mediated
by cellular factors.  Mol Cell Biol 1995, 15:4606-4615.
18. Jacquenet S, Mereau A, Bilodeau PS, Damier L, Stoltzfus CM, Branlant
C: A second exon splicing silencer within human immunode-
ficiency virus type 1 tat exon 2 represses splicing of Tat
mRNA and binds protein hnRNP H.  J Biol Chem 2001,
276:40464-40475.
19. Wentz MP, Moore BE, Cloyd MW, Berget SM, Donehower LA: A
naturally arising mutation of a potential silencer of exon
splicing in human immunodeficiency virus type 1 induces
dominant aberrant splicing and arrests virus production.  J
Virol 1997, 71:8542-8551.
20. Caputi M, Zahler AM: SR proteins and hnRNP H regulate the
splicing of the HIV-1 tev-specific exon 6D.  EMBO J 2002,
21:845-855.
21. Staffa A, Cochrane A: Identification of positive and negative
splicing regulatory elements within the terminal tat-rev
exon of human immunodeficiency virus type 1.  Mol Cell Biol
1995, 15:4597-4605.
22. Tange TO, Damgaard CK, Guth S, Valcarcel J, Kjems J: The hnRNP
A1 protein regulates HIV-1 tat splicing via a novel intron
silencer element.  EMBO J 2001, 20:5748-5758.
23. Caputi M, Freund M, Kammler S, Asang C, Schaal H: A bidirectional
SF2/ASF- and SRp40-dependent splicing enhancer regulates
human immunodeficiency virus type 1 rev, env, vpu, and nef
gene expression.  J Virol 2004, 78:6517-6526.
24. Marchand V, Mereau A, Jacquenet S, Thomas D, Mougin A, Gattoni R,
Stevenin J, Branlant C: A janus splicing regulatory element
modulates HIV-1 tat and rev mRNA production by coordina-
tion of hnRNP A1 cooperative binding.  J Mol Biol 2002,
323:629-652.
25. Tange TO, Kjems J: SF2/ASF binds to a splicing enhancer in the
third HIV-1 tat exon and stimulates U2AF binding independ-
ently of the RS domain.  J Mol Biol 2001, 312:649-662.
26. Zhu J, Mayeda A, Krainer AR: Exon identity established through
differential antagonism between exonic splicing silencer-
bound hnRNP A1 and enhancer-bound SR proteins.  Mol Cell
2001, 8:1351-1361.
27. O'Reilly MM, McNally MT, Beemon KL: Two strong 5' splice sites
and competing, suboptimal 3' splice sites involved in alterna-
tive splicing of human immunodeficiency virus type 1 RNA.
Virology 1995, 213:373-385.
28. Kammler S, Leurs C, Freund M, Krummheuer J, Seidel K, Tange TO,
Lund MK, Kjems J, Scheid A, Schaal H: The sequence complemen-
tarity between HIV-1 5' splice site SD4 and U1 snRNA deter-
mines the steady-state level of an unstable env pre-mRNA.
RNA 2001, 7:421-434.
29. Freund M, Asang C, Kammler S, Konermann C, Krummheuer J, Hipp
M, Meyer I, Gierling W, Theiss S, Preuss T, Schindler D, Kjems J,
Schaal H: A novel approach to describe a U1 snRNA binding
site.  Nucleic Acids Res 2003, 31:6963-6975.
30. Swanson AK, Stoltzfus CM: Overlapping cis sites used for splic-
ing of HIV-1 env/nef and rev mRNAs.  J Biol Chem 1998,
273:34551-34557.
31. Benko DM, Schwartz S, Pavlakis GN, Felber BK: A novel human
immunodeficiency virus type 1 protein, tev, shares
sequences with tat, env, and rev proteins.  J Virol 1990,
64:2505-2518.
32. Caputi M, Mayeda A, Krainer AR, Zahler AM: hnRNP A/B proteins
are required for inhibition of HIV-1 pre-mRNA splicing.
EMBO J 1999, 18:4060-4067.
33. Si ZH, Rauch D, Stoltzfus CM: The exon splicing silencer in
human immunodeficiency virus type 1 Tat exon 3 is bipartite
and acts early in spliceosome assembly.  Mol Cell Biol 1998,
18:5404-5413.
34. Freund M: Die Funktion des U1 snRNPs in der HIV-1 env-
expression.  Heinrich-Heine-Universität Düsseldorf, Institut für
Virologie; 2004. 
35. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A
web resource to identify exonic splicing enhancers.  Nucleic
Acids Res 2003, 31:3568-3571.
36. Madsen JM, Stoltzfus CM: A suboptimal 5' splice site down-
stream of HIV-1 splice site A1 is required for unspliced viral
mRNA accumulation and efficient virus replication.  Retrovirol-
ogy 2006, 3:10.
37. Lu XB, Heimer J, Rekosh D, Hammarskjold ML: U1 small nuclear
RNA plays a direct role in the formation of a rev-regulated
human immunodeficiency virus env mRNA that remains
unspliced.  Proc Natl Acad Sci U S A 1990, 87:7598-7602.
38. Freund M, Hicks MJ, Konermann C, Otte M, Hertel KJ, Schaal H:
Extended base pair complementarity between U1 snRNA
and the 5' splice site does not inhibit splicing in higher
eukaryotes, but rather increases 5' splice site recognition.
Nucleic Acids Res 2005, 33:5112-5119.
39. Nasioulas G, Zolotukhin AS, Tabernero C, Solomin L, Cunningham
CP, Pavlakis GN, Felber BK: Elements distinct from human
immunodeficiency virus type 1 splice sites are responsiblePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2006, 3:89 http://www.retrovirology.com/content/3/1/89
Page 20 of 20
(page number not for citation purposes)
for the Rev dependence of env mRNA.  J Virol 1994,
68:2986-2993.
40. Fischer U, Meyer S, Teufel M, Heckel C, Luhrmann R, Rautmann G:
Evidence that HIV-1 Rev directly promotes the nuclear
export of unspliced RNA.  EMBO J 1994, 13:4105-4112.
41. Query CC, Strobel SA, Sharp PA: Three recognition events at
the branch-site adenine.  EMBO J 1996, 15:1392-1402.
42. Smith CW, Chu TT, Nadal Ginard B: Scanning and competition
between AGs are involved in 3' splice site selection in mam-
malian introns.  Mol Cell Biol 1993, 13:4939-4952.
43. Amendt BA, Hesslein D, Chang LJ, Stoltzfus CM: Presence of neg-
ative and positive cis-acting RNA splicing elements within
and flanking the first tat coding exon of human immunodefi-
ciency virus type 1.  Mol Cell Biol 1994, 14:3960-3970.
44. Si ZH, Amendt BA, Stoltzfus CM: Splicing efficiency of human
immunodeficiency virus type 1 tat RNA is determined by
both a suboptimal 3' splice site and a 10 nucleotide exon
splicing silencer element located within tat exon.  Nucleic Acids
Res 1997, 25:861-867.
45. Cochrane AW, McNally MT, Mouland AJ: The retrovirus RNA
trafficking granule: from birth to maturity.  Retrovirology 2006,
3:18.
46. Damgaard CK, Tange TO, Kjems J: hnRNP A1 controls HIV-1
mRNA splicing through cooperative binding to intron and
exon splicing silencers in the context of a conserved second-
ary structure.  RNA 2002, 8:1401-1415.
47. Jacquenet S, Decimo D, Muriaux D, Darlix JL: Dual effect of the SR
proteins ASF/SF2, SC35 and 9G8 on HIV-1 RNA splicing and
virion production.  Retrovirology 2005, 2:33.
48. Bilodeau PS, Domsic JK, Stoltzfus CM: Splicing regulatory ele-
ments within tat exon 2 of human immunodeficiency virus
type 1 (HIV-1) are characteristic of group M but not group O
HIV-1 strains.  J Virol 1999, 73:9764-9772.
49. Zahler AM, Damgaard CK, Kjems J, Caputi M: SC35 and heteroge-
neous nuclear ribonucleoprotein A/B proteins bind to a jux-
taposed exonic splicing enhancer/exonic splicing silencer
element to regulate HIV-1 tat exon 2 splicing.  J Biol Chem
2004, 279:10077-10084.
50. Chen D, Wang M, Zhou S, Zhou Q: HIV-1 Tat targets microtu-
bules to induce apoptosis, a process promoted by the pro-
apoptotic Bcl-2 relative Bim.  EMBO J 2002, 21:6801-6810.
51. Muthumani K, Choo AY, Hwang DS, Chattergoon MA, Dayes NN,
Zhang D, Lee MD, Duvvuri U, Weiner DB: Mechanism of HIV-1
viral protein R-induced apoptosis.  Biochem Biophys Res Commun
2003, 304:583-592.
52. Bohne J, Wodrich H, Krausslich HG: Splicing of human immuno-
deficiency virus RNA is position-dependent suggesting
sequential removal of introns from the 5' end.  Nucleic Acids Res
2005, 33:825-837.
53. Tange TO, Jensen TH, Kjems J: In vitro interaction between
human immunodeficiency virus type 1 Rev protein and splic-
ing factor ASF/SF2-associated protein, p32.  J Biol Chem 1996,
271:10066-10072.
54. Jacquenet S, Ropers D, Bilodeau PS, Damier L, Mougin A, Stoltzfus
CM, Branlant C: Conserved stem-loop structures in the HIV-1
RNA region containing the A3 3' splice site and its cis-regu-
latory element: possible involvement in RNA splicing.  Nucleic
Acids Res 2001, 29:464-478.
55. Cabello-Villegas J, Giles KE, Soto AM, Yu P, Mougin A, Beemon KL,
Wang YX: Solution structure of the pseudo-5' splice site of a
retroviral splicing suppressor.  RNA 2004, 10:1388-1398.
56. Tazi J, Durand S, Jeanteur P: The spliceosome: a novel multi-fac-
eted target for therapy.  Trends Biochem Sci 2005, 30:469-478.
57. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, Fic W,
Divita G, Rivalle C, Dauzonne D, Nguyen CH, Jeanteur P, Tazi J:
Selective modification of alternative splicing by indole deriv-
atives that target serine-arginine-rich protein splicing fac-
tors.  Proc Natl Acad Sci U S A 2005, 102:8764-8769.
58. Schaal H, Klein M, Gehrmann P, Adams O, Scheid A: Requirement
of N-terminal amino acid residues of gp41 for human immu-
nodeficiency virus type 1-mediated cell fusion.  J Virol 1995,
69:3308-3314.
59. Schaal H, Pfeiffer P, Klein M, Gehrmann P, Scheid A: Use of DNA
end joining activity of a Xenopus laevis egg extract for con-
struction of deletions and expression vectors for HIV-1 Tat
and Rev proteins.  Gene 1993, 124:275-280.
60. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA:
The HIV 'A' (sor) gene product is essential for virus infectiv-
ity.  Nature 1987, 328:728-730.
61. Lenz C, Scheid A, Schaal H: Exon 1 leader sequences down-
stream of U5 are important for efficient human immunode-
ficiency virus type 1 gene expression.  J Virol 1997,
71:2757-2764.
62. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel
R:  The T4 gene encodes the AIDS virus receptor and is
expressed in the immune system and the brain.  Cell 1986,
47:333-348.
63. Chomczynski P, Sacchi N: Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform extrac-
tion.  Anal Biochem 1987, 162:156-159.
64. Madsen JM, Stoltzfus CM: An exonic splicing silencer down-
stream of the 3' splice site A2 is required for efficient human
immunodeficiency virus type 1 replication.  J Virol 2005,
79:10478-10486.
65. Mayeda A, Screaton GR, Chandler SD, Fu XD, Krainer AR: Sub-
strate specificities of SR proteins in constitutive splicing are
determined by their RNA recognition motifs and composite
pre-mRNA exonic elements.  Mol Cell Biol 1999, 19:1853-1863.
66. Asai K, Platt C, Cochrane A: Control of HIV-1 env RNA splicing
and transport: investigating the role of hnRNP A1 in exon
splicing silencer (ESS3a) function.  Virology 2003, 314:229-242.
67. HIV Sequence Database; Los Alamos National Laboratory
2006 [http://www.hiv.lanl.gov./content/hiv-db/CONSENSUS/
M_GROUP/Consensus.html].